Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07596901 | Study of Aritinercept in Patients With Generalized Myasthenia Gravis | PHASE1 | RECRUITING | 81 | — | — | Apr 22, 2026 | Mar 2, 2029 | May 19, 2026 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| Aritinercept | EXPERIMENTAL | Double-Blind Treatment Period: Aritinercept by subcutaneous injection Open-Label Treatment Period: Aritinercept by subcutaneous injection |
| Placebo | PLACEBO_COMPARATOR | Double-Blind Treatment Period: Placebo by subcutaneous injection Open-Label Treatment Period: Aritinercept by subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| Aritinercept | DRUG | For subcutaneous injection |
| Placebo | OTHER | For subcutaneous injection |
Key Inclusion Criteria: * Adult patients (18-85 years old) * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * Current or medical history of malignancy within the last 5 years * Pregnant, breastfeed...